Currently Viewing:
American Heart Association Scientific Sessions 2019
Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes
November 17, 2019
Dr Jay Edelberg Outlines the Clinical Burdens and Treatment Options for Hypertrophic Cardiomyopathy
November 17, 2019
Details of DAPA-HF Results Point to Dapagliflozin for Some Heart Failure Patients Without Diabetes
November 17, 2019
In Stable Heart Disease, Study Finds Stents Might Be No Better Than Drugs
November 17, 2019
Dapagliflozin Meets Quality-of-Life Marks, Efficacy Among Seniors, Data Show
November 17, 2019
From Self-Reporting Accuracy to Therapy Access: AHA Posters Cover Issues in Disparities
November 18, 2019
Dr John Pfeifer Outlines Necessary Steps for Preventive Action in Patients With Atrial Fibrillation
November 18, 2019
Sara Levintow Analyzes 2013 ACC/AHA Cholesterol Guidelines in Relation to Trends in US Lipid Testing
November 18, 2019
Plaques May Be Key to Vascepa's Role in Preventing CV Events
November 18, 2019
48-Week Results for Mavacamten Draw Crowd at AHA Session
November 19, 2019
Dr Vinay Kini Discusses the Growing Influence of the EHR in the Transition to Value-Based Care
November 19, 2019
Dr Stephen Heitner Details the Significance of the PIONEER-OLE Study in Treating Obstructive HCM
November 19, 2019
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
November 21, 2019
Dr Stephen Voyce Details Innovations and Preventive Strategies in Detection of Atrial Fibrillation
November 24, 2019
Dr Brent Williams Discusses Study Findings on Detection of Atrial Fibrillation
November 27, 2019
Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation
November 30, 2019
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 04, 2019
Currently Reading
Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH
December 05, 2019
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
December 06, 2019
Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD
January 03, 2020
Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure
January 11, 2020
Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM
January 16, 2020
Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten
January 26, 2020
Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation
January 31, 2020

Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH

The HDL PDS-2 system showed in a relatively short time its ability to affect the progression of HoFH, with a reduction in the burden of plaque overall highlighting its exciting potential, said Brian Ghoshhajra, MD, MBA, diagnostic radiologist and service chief of cardiovascular imaging in the Department of Radiology at Massachusetts General Hospital.


The HDL PDS-2 system showed in a relatively short time its ability to affect the progression of HoFH, with a reduction in the burden of plaque overall highlighting its exciting potential, said Brian Ghoshhajra, MD, MBA, diagnostic radiologist and service chief of cardiovascular imaging in the Department of Radiology at Massachusetts General Hospital.

Transcript

Can you discuss the initial intrigue in utilizing an acute care therapeutic device, PDS-2, as a treatment for HoFH?

The type of disease (HoFH) that we see in the first 2 decades of life is actually the kind of disease that otosclerotic patients more classically get in the last 2 decades of life. So, the ability to affect that progression–in the observation we made was that the plaque change is very intriguing. The HDL PDS-2 system is administered over a short time. So, in just 7 weeks, 7 treatments, we've observed pretty significant changes. The trial is exciting for me as well because it's one of the first times that CT angiography (CTA) could be used–we're seeing that a lot of the meeting (AHA 2019). CTA is being implemented and that's where my team came in, where we analyze the CT angiography. So, we're able to assay the entire burden of plaque in all of the arteries and find the most concerning ones, which aren't necessarily the most stenotic ones, but the ones with the biggest plaque burden. We’re able to measure that and then in a short time measure it again after the therapy, and we saw a pretty remarkable reduction in the burden of plaque overall.

It's worth stepping back and looking at what CTA can show you–we can measure the entirety of the plaque burden, but we can also look at the subtypes of plaque. If you could choose, you would have no plaque in the coronary arteries, but in this case, we have the amount of plaque burden overall, and then the amount of calcified portion that's fairly thought to be more stable. A good marker that you have is otosclerosis, but the more concerning part is the lower density plaque. Then there's a subtype where the necrotic core, which is the highest risk conferring. So, when you have plaques, you have risk of future rupture and those are the ones that are most associated with risk, and this is the one that changed most dramatically in the short time that we did the therapy.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up